Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
NCT00006734 · View on ClinicalTrials.gov ↗
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which chemotherapy regimen combined with radiation therapy and/or surgery is more effective in treating Ewing's sarcoma or primitive neuroectodermal tumor. PURPOSE: Randomized phase III trial to compare the effectiveness of different chemotherapy regimens combined with radiation therapy and/or surgery in treating patients who have Ewing's sarcoma or primitive neuroectodermal tumor.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- DRUG ifosfamide
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
Study Locations (20)
California
- Southern California Permanente Medical Group — Downey
- City of Hope Comprehensive Cancer Center — Duarte
- Rebecca and John Moores UCSD Cancer Center — La Jolla
- Loma Linda University Cancer Institute at Loma Linda University Medical Center — Loma Linda
- Jonathan Jaques Children's Cancer Center at Miller Children's Hospital — Long Beach
- Children's Hospital Los Angeles — Los Angeles
- Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center — Los Angeles
- Jonsson Comprehensive Cancer Center at UCLA — Los Angeles
- Children's Hospital Central California — Madera
- Children's Hospital and Research Center at Oakland — Oakland
- Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center — Orange
- Children's Hospital of Orange County — Orange
- Lucile Packard Children's Hospital at Stanford University Medical Center — Palo Alto
- Sutter Cancer Center — Sacramento
- University of California Davis Cancer Center — Sacramento
Alabama
- Comprehensive Cancer Center at University of Alabama at Birmingham — Birmingham
- University of South Alabama Cancer Research Institute — Mobile
Arizona
- Phoenix Children's Hospital — Phoenix
- Arizona Cancer Center at University of Arizona Health Sciences Center — Tucson
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences — Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 587 participants |
| Start Date | 2001-05 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006734
The ClinicalTrials.gov registry entry for NCT00006734 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 587 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 318 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 5 interventions — of which cyclophosphamide is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00006734 reports 20 study locations spanning 4 distinct geographic areas — top geographies include California, Alabama, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00006734 about?
NCT00006734 is a clinical study titled "Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor". RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which chemotherapy regimen combined with radiation therapy and/or surgery is more effective...
What is the current status of trial NCT00006734?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 587 participants. The study started on 2001-05. Estimated completion is 2023-06-30.
What conditions does trial NCT00006734 study?
This clinical trial studies the following conditions: Sarcoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00006734?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), ifosfamide (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00006734?
This trial is sponsored by Children's Oncology Group, which has 318 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00006734 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.